$2.82
19.43%
Nasdaq, Fri, Nov 15 2024
ISIN
US09076G1040
Symbol
BPTS
Sector
Industry

Biophytis - ADR Stock price

$2.82
-0.99 25.89% 1M
-5.38 65.61% 6M
-24.01 89.49% YTD
-27.53 90.71% 1Y
-2,353.18 99.88% 3Y
-6,597.18 99.96% 5Y
-6,597.18 99.96% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.68 19.43%
ISIN
US09076G1040
Symbol
BPTS
Sector
Industry

Key metrics

Market capitalization $1.48m
Enterprise Value $9.50m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.72m
Free Cash Flow (TTM) Free Cash Flow $-12.51m
EPS (TTM) EPS $-15,420.51
P/E forward negative
Short interest 0.02%
Show more

Is Biophytis - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Biophytis - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Biophytis - ADR:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Biophytis - ADR:

Hold
100%

Financial data from Biophytis - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.87 0.87
74% 74%
-
-0.87 -0.87
74% 74%
-
- Selling and Administrative Expenses 3.69 3.69
12% 12%
-
- Research and Development Expense 9.30 9.30
39% 39%
-
-14 -14
30% 30%
-
- Depreciation and Amortization 0.87 0.87
74% 74%
-
EBIT (Operating Income) EBIT -15 -15
28% 28%
-
Net Profit -16 -16
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biophytis - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biophytis - ADR Stock News

Neutral
Accesswire
about 2 months ago
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing treatments for age-related diseases, publishes today its financial results for the first half of 2024 and provides an update on the company's key achievements. Stanislas Veillet, CEO of Biophyt...
AD HOC NEWS
about 2 months ago
Biophytis / US09076G1040
Neutral
Accesswire
4 months ago
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two...
More Biophytis - ADR News

Company Profile

Biophytis SA is a holding company. It engages in the clinical development of therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. The firm develops drug candidates targeting diseases of aging. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.

Head office France
CEO Stanislas Veillet
Founded 2006
Website www.biophytis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today